Ligand Pharmaceuticals Incorporated reported $291M of revenue over the trailing twelve months, +55% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $291M (to Q2 2026). Net income: $197M, trailing twelve months to Q2 2026. Free cash flow: $131M, trailing twelve months to Q2 2026. Operating margin: 29%, trailing twelve months to Q2 2026.

LGNDLigand Pharmaceuticals Incorporated

Healthcare

$301.78+81% 1Y

$301.78

$166.7652 weeks$316.44

LGND as reported

Ligand Pharmaceuticals Incorporated reported $291M of revenue over the trailing twelve months, +55% on the year before. 11 reported series are charted on this page, each one as filed.

$291M

Revenue, trailing twelve months · to Q2 2026 · +55% against the twelve months before

Net income: $197M
Net income · −360% year on year · trailing twelve months to Q2 2026
Free cash flow: $131M
Free cash flow · +145% year on year · trailing twelve months to Q2 2026
Operating margin: 29%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for LGND, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$291M	+55%	Q2 2026
Net income	$197M	−360%	Q2 2026
EPS	$9.41	−333%	Q2 2026
Gross margin	91%	n/a	Q3 2019 · 27 quarters behind
Operating margin	29%	n/a	Q2 2026
Net margin	57%	n/a	Q2 2026
ROE	13%	n/a	Q2 2026
ROA	7.6%	n/a	Q2 2026
ROIC	−0.51%	n/a	Q1 2015 · 45 quarters behind
Free cash flow	$131M	+145%	Q2 2026
P/E	32.1	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.